Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Egyptian International Pharmaceutical Investments's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 23.72%.
CAI:PHAR's ROC (Joel Greenblatt) % is ranked better than 66.8% of 982
companies
in the Drug Manufacturers industry
Industry Median: 11.28
vs CAI:PHAR: 21.94
Egyptian International Pharmaceutical Investments (CAI:PHAR) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egyptian International Pharmaceutical Investments ROC (Joel Greenblatt) % Chart
Egyptian International Pharmaceutical Investments Annual Data
CAI:PHAR vs ZTS, UTHR, VTRS: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Egyptian International Pharmaceutical Investments's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Egyptian International Pharmaceutical Investments ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
Egyptian International Pharmaceutical Investments ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 23.72% mean?
Egyptian International Pharmaceutical Investments (CAI:PHAR) has a ROC (Joel Greenblatt) % of 23.72% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Egyptian International Pharmaceutical Investments and its competitors. This is 32% below median its historical median of 34.83. Over the past decade, Egyptian International Pharmaceutical Investments' ROC (Joel Greenblatt) % has ranged from 21.94 to 71.96. According to the industry distribution chart, Egyptian International Pharmaceutical Investments ranks #326 out of 982 companies in the Drug Manufacturers industry, placing it in the top 33.2%.
Is Egyptian International Pharmaceutical Investments' ROC (Joel Greenblatt) % too high?
Egyptian International Pharmaceutical Investments' current ROC (Joel Greenblatt) % of 23.72% is 32% below median its 10-year median of 34.83. Over the past 10 years, this metric has ranged from a low of 21.94 to a high of 71.96. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.28. Egyptian International Pharmaceutical Investments' value of 23.72% is 110.3% above this industry median. Based on the distribution chart, Egyptian International Pharmaceutical Investments ranks #326 out of 982 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Egyptian International Pharmaceutical Investments has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egyptian International Pharmaceutical Investments' ROC (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Egyptian International Pharmaceutical Investments ranks #326 out of 982 companies for ROC (Joel Greenblatt) %. This puts Egyptian International Pharmaceutical Investments in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 11.28. Egyptian International Pharmaceutical Investments' value of 23.72% is 110.3% above this benchmark. Historically, Egyptian International Pharmaceutical Investments' own ROC (Joel Greenblatt) % has ranged from 21.94 to 71.96 over the past decade. While the company's 10-year median is 34.83 vs. the industry median of 11.28, Egyptian International Pharmaceutical Investments has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.28, based on 982 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Egyptian International Pharmaceutical Investments's current ROC (Joel Greenblatt) % of 23.72% is 110.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Egyptian International Pharmaceutical Investments and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Egyptian International Pharmaceutical Investments's current ROC (Joel Greenblatt) % is 23.72%, which is 32% below median its own 10-year median of 34.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egyptian International Pharmaceutical Investments stock overvalued right now?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments (CAI:PHAR) is currently considered Significantly Overvalued. The stock's GF Value™ is E£60.01, compared to a current price of E£130.05 — trading 116.7% above its estimated fair value. The current ROC (Joel Greenblatt) % is 23.72%, which is 32% below median its 10-year median of 34.83 and 110.3% above the Drug Manufacturers industry median of 11.28. Egyptian International Pharmaceutical Investments' overall GF Score™ is 62/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Egyptian International Pharmaceutical Investments (CAI:PHAR), the current ROC (Joel Greenblatt) % is 23.72% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Egyptian International Pharmaceutical Investments (CAI:PHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments stock appears to be overvalued.
The current stock price of E£130.05 is trading 116.7% above its estimated GF Value™ of E£60.01.
GuruFocus considers Egyptian International Pharmaceutical Investments to be Significantly Overvalued.
Key valuation signals for CAI:PHAR:
ROC (Joel Greenblatt) %: 23.72% (32% below median its 10-year median of 34.83)
GF Value™: E£60.01 vs. price of E£130.05 (116.7% above fair value)
Industry Position: 110.3% above the Drug Manufacturers median (#326 of 982)
No single metric tells the full story. See the CAI:PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, Antibiotics, Lyophilized Products. It exports its products to African, Asian and East European and Latin American Countries.
62GF Score
Get the complete analysis for CAI:PHAR
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:PHAR has been successfully added to your 
